The estimated Net Worth of Donald A Denkhaus is at least $9.32 Million dollars as of 15 February 2024. Mr. Denkhaus owns over 4,000 units of Catalyst Pharmaceuticals Inc stock worth over $8,529,960 and over the last 10 years he sold CPRX stock worth over $638,600. In addition, he makes $151,064 as Independent Director at Catalyst Pharmaceuticals Inc.
Donald has made over 23 trades of the Catalyst Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of CPRX stock worth $77,840 on 15 February 2024.
The largest trade he's ever made was exercising 60,000 units of Catalyst Pharmaceuticals Inc stock on 3 August 2023 worth over $67,800. On average, Donald trades about 15,524 units every 93 days since 2015. As of 15 February 2024 he still owns at least 438,333 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Mr. Denkhaus stock trades at the bottom of the page.
Donald A. Denkhaus is Independent Director of Catalyst Pharmaceutical Partners, Inc. Since 2005, Mr. Denkhaus has been Chairman and Chief Financial Officer of The Kitchen, LLC, a company providing language dubbing and subtitling services to the television industry. From 1970 through 2002, Mr. Denkhaus, who is a retired certified public accountant, worked for Arthur Andersen LLP, a global professional services organization, where he was an audit partner for twenty-two years and held numerous leadership positions, including as head of Andersen’s South Florida audit practice and, from 1998 through 2002, as Audit Practice Partner responsible for Andersen’s offices in Florida and Puerto Rico. From 2010 to 2013, Mr. Denkhaus was Chair of Nuovo Biologics, a privately held biotech company that was developing an antiviral drug for animal use, and, from 2004 until its sale in 2009, Mr. Denkhaus served on the board of directors and as chair of the audit committee of Noven Pharmaceuticals, a publicly-traded specialty pharmaceutical company focused on women’s health and psychiatry. Mr. Denkhaus received a Master’s in Business Administration degree with a major in finance from the University of Maryland and a Bachelors of Business Administration with a major in accounting from Kent State University. The Board believes that the characteristics that qualify Mr. Denkhaus to be a member of our Board include his extensive financial experience and his prior experience serving as a director of two pharmaceutical companies, one of which was publicly-traded.
As the Independent Director of Catalyst Pharmaceuticals Inc, the total compensation of Donald Denkhaus at Catalyst Pharmaceuticals Inc is $151,064. There are 11 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of $3,371,560.
Donald Denkhaus is 74, he's been the Independent Director of Catalyst Pharmaceuticals Inc since 2015. There are 1 older and 14 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
Donald's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134.
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany und Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: